TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.

TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its iron oxide nanoparticle delivery platform, the Company has ...

Media transcoding is coming to the Microsoft PowerToys Advanced Paste tool (transcode audio and video from a copy/paste context menu) ...

TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns.

TransCode Therapeutics recently received approval for a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers. In this clinical trial, up to 12 patients will be given a ...

TransCode Therapeutics Inc RNAZ shares are trading higher Thursday after the company announced it received written authorization from the FDA to proceed with its First-in-Human Phase 0 clinical ...

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect TransCode Therapeutics ...

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday ...

--TransCode Therapeutics, Inc., the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business ...

View TransCode Therapeutics, Inc. RNAZ stock quote prices, financial information, real-time forecasts, and company news from CNN.